The Bulletin
The Times


.

Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I I Conditions and U.S. FDA Clearance of IND Application for BBT001

  • Written by PR Newswire
Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I I Conditions and U.S. FDA Clearance of IND Application for BBT001
  • Preclinical data with BBT002 demonstrate its best-in-disease potential for improved efficacy and dosing convenience across respiratory, dermatology, and gastroenterology indications
  • Interim safety and pharmacokinetic data from BBT002-01 study anticipated in Q1 2026
  • The clearance of BBT001-01 study expands the clinical development territory of BBT001...
hacklink esim balkanSahabetuk casinos not on gamstopGamStopgrandpashabet girisjojobetviagra 100 mg fiyat